| Date | Title | Description |
| 03.04.2026 | Ambrosia Biosciences Fuels Next-Gen Oral Metabolic Drug Development | Ambrosia Biosciences secured a monumental $100 million Series B funding. This capital injection immediately accelerates their oral small molecule GLP-1 candidate into pivotal clinical trials. It also vigorously advances their broader pipeli... |
| 01.04.2026 | Ambrosia Biosciences: $100 Million Raised For Cardiometabolic Small Molecule Pipeline Advancement | Ambrosia Biosciences announced that it has raised $100 million in an oversubscribed Series B financing round to advance its pipeline of orally delivered small molecule therapies targeting cardiometabolic diseases.
The financing was co-led b... |
| 31.03.2026 | Ambrosia Biosciences Raises $100M in Series B Funding | Ambrosia Biosciences, a Boulder, CO-based drug discovery company, raised $100M in Series B funding.
The round was led by Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital, with participation from existing investors BVF Partn... |
| 30.03.2026 | A retirement saver protection rule has died — for the second time. What it means for investors | The Department of Labor fiduciary rule had raised the legal bar for brokers, insurance agents, financial advisors and others who advised investors to roll over assets from a 401(k) plan to an individual retirement account.
The Obama and Bid... |
| 26.03.2026 | Use options to play a potential Invesco runup in wake of Janus Henderson deal | - |
| 24.03.2026 | Janus Henderson bidding war heats up as Trian and General Catalyst raises offer | Nelson Peltz’s Trian Fund Management and General Catalyst have upped their cash offer for Janus Henderson, heating up the bidding war with Victory Capital.
Trian and a group of investors led by General Catalyst said on Tuesday they had incr... |
| 24.03.2026 | Trian and General Catalyst Agree to Increase Merger Consideration to $52.00 Per Share in Cash for Janus Henderson Group plc and Have Made the Only Actionable Proposal | Janus Henderson Group plc (NYSE: JHG; “Janus Henderson,” or the “Company”) announced that Trian Fund Management, L.P. and its affiliated funds (“Trian”), General Catalyst Group Management, LLC and its affiliated funds (“General Catalyst”) a... |
| 19.03.2026 | Asset Management Titans Clash: Janus Henderson Bidding War Heats Up Amidst Industry Reshaping | A fierce bidding war for asset manager Janus Henderson intensifies. Victory Capital presents an increased, higher-valued offer. However, the Janus Henderson board continues to back a rival bid from Trian Fund Management and General Catalyst... |
| 18.03.2026 | City AM Awards 2026: Meet the Finalists | The City AM Awards are back and this year our finalists are stronger than ever. Our judges now have the task of voting for an overall winner in each category, to be announced at the Guildhall on May 6. And the nominees are….
Greg Jackson CB... |
| 17.03.2026 | Victory Capital raises offer as Janus Henderson bidding war heats up | Victory Capital has increased its offer for rival asset manager Janus Henderson as the bidding war with Trian Fund Management and General Catalyst heats up.
The latest offer from Texas-based Victory Capital comes just days after its previou... |
| 17.03.2026 | Janus Henderson Special Committee Confirms Receipt of Revised Unsolicited, Non-Binding Proposal from Victory Capital | Janus Henderson Group plc (NYSE: JHG; “JHG, ” “Janus Henderson, ” or the “Company”) today confirmed that on March 17, 2026, the Special Committee (the “Special Committee”) of the Janus Henderson Board of Directors (the “Board”) received a r... |
| 11.03.2026 | Janus Henderson Group plc Board of Directors Determines by Unanimous Vote that Victory Capital’s Proposal Is Not Superior and Reaffirms Recommendation of Transaction with Trian and General Catalyst | Janus Henderson Group plc (NYSE: JHG; “JHG,” “Janus Henderson,” or the “Company”) today announced that its Board of Directors (the “Board”), acting on the unanimous recommendation of the Special Committee of the Board (the “Special Committe... |
| 09.03.2026 | HEART ON WHEELS 2026 Sees Community Come Together to Raise 33,400 Food Items for Families in Need | HEART ON WHEELS 2026 once again brought together automotive convoys, corporate partners, and local communities to contribute 33,400 food items, surpassing its 28,000 target. With this, since its inaugural edition in 2023, the event has rais... |
| 04.03.2026 | Poplar Therapeutics Raises $45M in Series A Extension Funding | Poplar Therapeutics, a Cambridge, MA-based clinical-stage immunology company, raised $45M in Series A extension funding.
The round was led by Janus Henderson Investors, with participation from RA Capital, SR One, Vida Ventures and affiliate... |
| 03.03.2026 | Poplar Therapeutics: $45 Million Series A Extension Raised By Immunology Company To Advance Anti-IgE Therapy PHB-050 | Poplar Therapeutics, a clinical-stage immunology company developing a new class of anti-IgE therapy for food allergy and other atopic conditions, has closed a $45 million Series A extension, bringing its total Series A financing to $95 mill... |
| 01.03.2026 | Victory Capital разжигает борьбу за Janus Henderson: новое предложение на $8,6 млрд | Американская инвестиционная компания Victory Capital выступила с неожиданной инициативой по покупке глобального управляющего активами Janus Henderson за $8,6 млрд, что может запустить полноценную конкурентную борьбу за контроль над компание... |
| 26.02.2026 | Janus Henderson Confirms Receipt of Unsolicited, Non-Binding Proposal | Janus Henderson Group plc (NYSE: JHG; “JHG,” “Janus Henderson,” or the “Company”) today confirmed that the Special Committee of the Janus Henderson Board of Directors (the “Special Committee”) received an unsolicited, non-binding proposal.
... |
| 26.02.2026 | Nvidia’s blowout earnings report disappoints Wall Street as stock sinks 5% | The company reported stellar quarterly results, but the numbers were not enough to assuage Wall Street amid an already fragile time for stocks.
Investors are pointing to Nvidia’s stalling $100 billion deal with ChatGPT maker OpenAI as one p... |
| 23.02.2026 | Janus Henderson Launches AA-A CLO ETF Backed By $100 Million Seed Investment | Janus Henderson Investors has launched the Janus Henderson AA-A CLO ETF, expanding its active fixed-income ETF lineup in the securitized markets segment. The new fund debuted with $100 million in seed capital from The Guardian Life Insuranc... |
| 21.02.2026 | Five key takeaways from the Supreme Court’s landmark decision against Trump’s tariffs | The Supreme Court’s decision to throw out a large number of tariffs that President Donald Trump imposed on imports was widely expected. What’s far less certain is the longer-run impacts.
The path from here will be complicated, but Trump in ... |
| 21.02.2026 | Korsana Biosciences Launches With $175 Million To Advance Alzheimer’s Therapeutics | Korsana Biosciences, a biotechnology company focused on discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, announced its emergence from stealth with $175 million in funding from a syndicate of hea... |
| 18.02.2026 | Korsana Biosciences Raises $175M in Funding | Korsana Biosciences, a Waltham, MA-based biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, raised $175M in total funding.
The amount consisted of a $25M Seed investment from... |
| 17.02.2026 | U.S. Job Market Shows Mixed Signals Amid January Surge | U.S. job growth surged in January 2026, adding 130,000 nonfarm payrolls. Unemployment fell to 4.3%. This beat market expectations. The positive report offers a glimmer of hope. However, economic experts express caution. Gains focused heavil... |
| 17.02.2026 | ILiAD Biotechnologies Secures $115M to Accelerate Advanced Pertussis Vaccine Development | ILiAD Biotechnologies, a clinical-stage biotech firm, raised $115 million in Series B funding. RA Capital Management led the investment. Janus Henderson and BNP Paribas Asset Management Alts also participated. The capital will advance BPZE1... |
| 16.02.2026 | Janus Henderson Affiliates Privacore Capital And Victory Park Capital Launch Interval Fund Focused On Private Asset-Backed Credit | Janus Henderson Group announced that its affiliates Privacore Capital and Victory Park Capital have launched the Privacore VPC Asset Backed Credit Fund, the firms’ first registered interval fund targeting private asset-backed credit opportu... |
| 12.02.2026 | Tech IPO hype gets drowned out on Wall Street by prospect of $1 trillion in debt sales | A prospective SpaceX IPO is boosting enthusiasm on Wall Street, but all the current action in tech capital markets is on the debt side.
UBS estimates that tech and AI-related debt issuance across the globe more than doubled to $710 billion ... |
| 11.02.2026 | ILiAD Biotechnologies Raises $115M in Series B Funding | ILiAD Biotechnologies, a Weston, FL-based clinical stage biotech company, raised $115M in Series B funding.
The round was led by RA Capital Management with participation from new investors Janus Henderson Investors and BNP Paribas Asset Man... |
| 11.02.2026 | U.S. payrolls rose by 130,000 in January, more than expected; unemployment down to 4.3% | Nonfarm payrolls increased by 130,000 for January, above the Dow Jones consensus estimate for 55,000.
The unemployment rate edged lower to 4.3%. A more encompassing measure slipped to 8%, down 0.4 percentage point from December.
As has ofte... |
| 10.02.2026 | ILiAD Biotechnologies: $115 Million Series B Closed To Advance Intranasal Pertussis Vaccine | ILiAD Biotechnologies, an advanced clinical stage biotechnology company focused on preventing and treating disease caused by Bordetella pertussis, announced it has closed an oversubscribed $115 million Series B financing to advance BPZE1, i... |
| 10.02.2026 | ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine | ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the successful closing of an oversubscribed $115 million Seri... |
| 03.02.2026 | CesiumAstro Secures $470M for AI-Enabled Space and Defense Expansion | CesiumAstro, an Austin-based leader in space and defense communications, closed a $470M Series C. This capital infusion fuels expanded manufacturing and AI-enabled communications. It scales Element LEO satellite production and grows global ... |
| 03.02.2026 | CesiumAstro: $470 Million Series C Closed To Scale AI-Enabled Space And Defense Communications | CesiumAstro announced it has secured $470 million in Series C growth capital to accelerate U.S. expansion and global deployment of its software-defined, AI-enabled space communications platforms. The Austin, Texas-based space and defense co... |
| 02.02.2026 | Tenpoint Therapeutics Secures $235M, Prepares YUVEZZI Launch for Presbyopia | Tenpoint Therapeutics secured $235 million in new capital. This robust funding fuels the impending launch of YUVEZZI. YUVEZZI is an FDA-approved, first-of-its-kind dual-agent eye drop. It targets presbyopia, a widespread aging vision condit... |
| 02.02.2026 | CesiumAstro Closes $470M in Series C Funding | CesiumAstro, an Austin, TX-based company developing connectivity solutions for space and defense, raised $470M in Series C funding.
The round consisted of a $270M in equity, led by Trousdale Ventures, with participation from Woven Capital, ... |
| 31.01.2026 | TRexBio Secures $50M to Accelerate Treg-Targeted Immunotherapy Pipeline | TRexBio secured $50 million. This clinical-stage biotech develops precision immunoregulatory medicines. Its focus: tissue regulatory T cell (Treg) biology. Funding fuels clinical and preclinical pipeline advancement. Lead program TRB 061, a... |
| 30.01.2026 | Tenpoint Therapeutics: $235 Million Raised To Launch YUVEZZI Presbyopia Eye Drop | Tenpoint Therapeutics has secured $235 million in new funding to support the planned commercialization of its presbyopia treatment, YUVEZZI. The company said the capital combines an $85 million Series B preferred stock financing and a $150 ... |
| 29.01.2026 | Tenpoint Therapeutics: $235 Million Raised To Launch Dual Agent Presbyopia Eye Drop YUVEZZI | Tenpoint Therapeutics said it has secured $235 million in new capital, combining an $85 million Series B preferred stock financing with a $150 million senior secured term loan facility, as the company prepares to commercialize its newly app... |
| 29.01.2026 | Tenpoint Therapeutics Raises $235M Through Series B and Credit Facility | Tenpoint Therapeutics, Ltd., a London, UK and Seattle, WA-based provider of vision rejuvenation treatments for the aging eye, raised $235m through a Series B stock financing and a credit facility.
The company raised $85m in Series B financi... |
| 28.01.2026 | TRexBio: $50 Million Raised To Advance Tissue-Targeted Treg Immunology Pipeline | TRex Bio, a clinical-stage biotechnology company focused on precision immunoregulatory medicines derived from tissue regulatory T cell biology, announced it closed an oversubscribed $50 million financing to support clinical and preclinical ... |
| 27.01.2026 | TRexBio Raises $50M in Funding | TRexBio, a San Francisco, CA-based clinical-stage biotechnology company, raised $50M in funding.
Backers included new investors Janus Henderson Investors, Balyasny Asset Management L.P. and Affinity Asset Advisors, as well as existing inves... |
| 27.01.2026 | Big Tech’s AI borrowing boom tests US bond market | Big Tech is on track to become the dominant force in the US corporate bond market, as the race to build AI infrastructure drives an unprecedented surge in borrowing that is beginning to worry investors.
By the end of the decade, around half... |
| 23.01.2026 | Janus Henderson Announces Acquisition of Richard Bernstein Advisors | Janus Henderson Group (NYSE: JHG) (“Janus Henderson” or the “Company”), a leading global asset manager, today announced it has entered into a definitive agreement to acquire 100% of Richard Bernstein Advisors (“RBA”), a research-driven, mac... |
| 22.01.2026 | Think Bioscience Secures $55M Series A for 'Undruggable' Target Therapies | Think Bioscience, a Boulder, CO-based drug discovery innovator, closed an oversubscribed $55 million Series A funding round. This substantial investment accelerates R&D and operational expansion. The firm pioneers small molecule therape... |
| 21.01.2026 | Think Bioscience: $55 Million Raised For Developing Small-Molecule Drugs | Think Bioscience, a Boulder, Colorado-based biotechnology company developing small-molecule drugs against historically difficult targets, has raised $55 million in an oversubscribed Series A financing to advance its internal pipeline of fir... |
| 20.01.2026 | Think Bioscience Raises $55M in Series A Funding | Think Bioscience, a Boulder, CO-based privately held small molecule drug discovery company, raised $55M in Series A funding.
The round was led byRegeneron Ventures, Innovation Endeavors, and Janus Henderson Investors with participation from... |
| 15.01.2026 | China just ‘months’ behind U.S. AI models, Google DeepMind CEO says | Skip the noise. Get the download.
Google DeepMind CEO Demis Hassabis told CNBC that Chinese AI models might be “a matter of months” behind U.S. and Western capabilities.
However, he noted that Chinese firms are yet to show the ability to pu... |
| 14.01.2026 | Caldera Therapeutics Launches with $112.5M in Total Capital | Caldera Therapeutics, Inc., a Cambridge, MA-based clinical stage biotechnology company, launched with $112.5M total capital raised.
The amount consisted of a $75M Series A round from Atlas Venture, LAV and venBio, and most recently a $37.5M... |
| 14.01.2026 | Caldera Therapeutics Launches With $112.5 Million And Doses First Subjects In Phase 1 Trial Of CLD-423 | Caldera Therapeutics, a clinical-stage biotechnology company developing a first-in-class bispecific antibody for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases, launched with $112.5 million in total capital... |
| 11.01.2026 | Diagonal Therapeutics Secures $125M to Propel Innovative Antibody Therapies | Diagonal Therapeutics secured $125M Series B funding. This advances DIAG723, a first-in-class clustering antibody. It targets hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). The Watertown biotech corre... |
| 11.01.2026 | Parabilis Medicines Secures $305 Million for Cancer Drug Revolution | Parabilis Medicines recently closed an oversubscribed $305 million Series F financing round. This substantial capital propels its lead cancer candidate, zolucatetide, towards pivotal clinical trials for desmoid tumors and other challenging ... |
| 11.01.2026 | Diagonal Therapeutics: $125 Million Series B Raised To Advance DIAG723 Clustering Antibody Into the Clinic | Diagonal Therapeutics announced it has raised $125 million in an oversubscribed Series B financing to advance its lead program, DIAG723, a first-in-class “clustering antibody” designed to correct dysregulated receptor signaling implicated i... |
| 09.01.2026 | Diagonal Therapeutics Raises $125M in Series B Financing | Diagonal Therapeutics, a Watertown, MA-based biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, raised $125M in Series B Funding.
The round was co-led by ... |
| 08.01.2026 | Parabilis Medicines: $305 Million Series F Raised To Advance Zolucatetide Program And Helicon Peptide Platform | Parabilis Medicines, a clinical-stage cancer drug developer, said it has closed an oversubscribed $305 million Series F financing to fund ongoing clinical development of its lead candidate FOG-001 (zolucatetide) across multiple tumor types ... |
| 08.01.2026 | Parabilis rockets ahead with $305M series F to 'upend the status quo' with tumor drug | Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that will fuel a pivotal push for its potential first-in-class cancer drug.
The funds come from a smorgasbord of existin... |
| 08.01.2026 | Parabilis Medicines Raises $305M Series F Funding | Parabilis Medicines, a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer, closed a $305m Series F financing.
The round was co-led by RA Capital Management, Fidelity Ma... |
| 25.12.2025 | Asset Management Giant Janus Henderson Acquired for $7.4 Billion in Major Industry Shakeup | Janus Henderson, a global asset manager, is being acquired for $7.4 billion by Trian Fund Management and General Catalyst. The all-cash deal, valued at $49 per share, represents an 18% premium to its unaffected price. This strategic move ta... |
| 25.12.2025 | Instacart Halts AI Pricing Experiments Amid Public Outcry | Instacart ended its controversial AI-driven pricing tests. The decision came after significant public scrutiny. Shoppers reported varied prices for identical items. Federal regulators questioned the practice. The move underscores growing co... |
| 23.12.2025 | 5 Things to Know
Novo Nordisk’s new obesity pill, Alphabet’s data center deal, the end of EV euphoria and more in Morning Squawk | Regulators approved the first-ever GLP-1 pill for treating obesity from Novo Nordisk.
Alphabet will acquire data center company Intersect for $4.75 billion in cash and assume its debt.
Instacart is ending its contentious AI-driven pricing t... |
| 23.12.2025 | Janus Henderson покупают инвестиционные компании Trian и General Catalyst за $7,4 млрд | Международная инвестиционная компания Janus Henderson будет приобретена за $7,4 млрд. О сделке договорились активистский инвестиционный фонд Trian и венчурная и private equity-компания General Catalyst, которые выступили совместными покупат... |
| 22.12.2025 | Asset manager Janus Henderson gets bought by Trian, General Catalyst for $7.4 billion | Trian and General Catalyst will pay $49 per share in cash, valuing Janus at about $7.4 billion. That represents a 6.5% premium to Janus’ Friday’s close.
The deal is expected to close in mid-2026, they said.
Asset manager Janus Henderson has... |
| 22.12.2025 | Janus Henderson Group plc to be Acquired by Trian Fund Management and General Catalyst for $7.4 Billion | Janus Henderson Group plc (NYSE: JHG) (“Janus Henderson”, “JHG”, or the “Company”), Trian Fund Management, L.P. and its affiliated funds (“Trian”), and General Catalyst Group Management, LLC and its affiliated funds (“General Catalyst”), an... |
| 19.12.2025 | Medline's Monumental IPO: A Beacon Amidst Market Turbulence | Medline's colossal $6.26 billion initial public offering seized market attention. The medical supply giant's debut stands as the largest U.S. offering since 2021. Its shares experienced a significant post-listing surge. This strong performa... |
| 17.12.2025 | The chart that has Michael Burry worried about the stock market | - |
| 17.12.2025 | Американский производитель медтоваров Medline привлек $6,26 млрд в крупнейшем IPO года | Акции Medline Inc. выросли на 21% в день начала торгов после того, как поставщик медицинской продукции привлек $6,26 млрд в крупнейшем первичном публичном размещении акций в этом году.
Торги начались по цене $35 за акцию против цены размеще... |
| 16.12.2025 | BlossomHill Therapeutics Raises $84M in Series B Extension Funding | BlossomHill Therapeutics, Inc., a San Diego, CA-based clinical-stage biopharmaceutical company, raised $84M in Series B extension funding.
The round was led by Janus Henderson Investors, Brahma Capital, and BioTrack Capital, and participati... |
| 28.11.2025 | FT: техногиганты назанимали миллиарды долларов для развития OpenAI | Крупнейшие технологические компании и инвестиционные фонды планируют привлечь около $100 млрд в виде займов для финансирования развития OpenAI, позволяя стартапу масштабировать вычислительную инфраструктуру без прямого принятия финансовых о... |
| 25.11.2025 | Caesar Teams Up with Centrifuge for Onchain Equity Issuance by Crypto-Native Firm | Caesar, the AI co-research platform, has become the crypto-native firm to take steps towards issuing onchain equity via a partnership with Centrifuge. Such a deployment would create a precedent for how token-native startups can mature into ... |
| 19.11.2025 | Artios Pharma Secures $115M to Advance Cancer Therapies | Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical tri... |
| 17.11.2025 | €99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 mi... |
| 17.11.2025 | Artios raises $115M Series D to accelerate first-in-class cancer therapies | Biotech company Artios today announced the successful close of an oversubscribed $115 million Series D financing.
Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer a... |
| 10.11.2025 | Janus Henderson Announces Appointment of Financial Advisor and Legal Counsel to the Special Committee of the Board of Directors | Janus Henderson Group plc (NYSE: JHG) (“Janus Henderson” or the “Company”) today announced that the independent special committee (the “Special Committee”) of the Company’s board of directors (the “Board”) has retained Goldman Sachs & C... |
| 03.11.2025 | Tubulis: Second Tranche Of €344 Million Series C Closed To Advance ADC Pipeline | Tubulis announced the second and final closing of its Series C financing round, bringing the total raised to €344 million ($401 million). The round included new investors Fidelity Management & Research Company, Janus Henderson Investors... |
| 30.10.2025 | Net Asset Value(s) | Net Asset Value(s)
Thu, Oct 30, 2025 08:08 CET Report this content
[30.10.25]
TABULA ICAV
Janus Henderson EUR AAA CLO Active Core UCITS ETF Valuation Date ISIN Code Shares in Issue Currency Share Redeemed since Previous Valuation NET Asset ... |
| 30.10.2025 | Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $ 401M) |
MUNICH, GERMANY, October 30, 2025 – Tubulis today announced a second and final closing of its Series C round totaling €344M (US $401M). The second closing brought in additional new investors Fidelity Management & Research Company, Janu... |
| 28.10.2025 | Wall St scales fresh highs on tech earnings, US-China trade optimism | Wall Street's main indexes posted record closing highs for the second day in a row on Monday (Oct 27) as investors were hopeful about the prospects for a US-China trade deal and looked forward to a week packed with high-profile technology e... |
| 24.10.2025 | Inflation rate hit 3.0% in September, lower than expected, long-awaited CPI report shows | The consumer price index showed a 0.3% increase on the month, putting the annual inflation rate at 3%, both lower than expected.
Excluding food and energy, core CPI showed a 0.2% monthly gain and an annual rate also at 3%, also less than fo... |
| 12.10.2025 | Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders | Star Therapeutics, an innovative clinical-stage biotechnology company, is dedicated to discovering and developing cutting-edge antibodies aimed at treating bleeding disorders and other medical conditions. The company recently announced the ... |
| 07.10.2025 | Janus Henderson Said to Oppose Advent’s $1.3 Billion U-blox Bid | - |
| 01.10.2025 | Star Therapeutics Raises $125M in Series D Financing | Star Therapeutics, a San Francisca, CA-based clinical stage biotechnology company discovering and developing antibodies for bleeding disorders and other diseases, raised $125M Series D funding.
The round was co-led by Sanofi Ventures and Vi... |
| 19.09.2025 | Global economy takes Trump shocks in stride, for now | Global economy takes Trump shocks in stride, for now
By Howard Schneider and Mark JohnSeptember 19, 20255:05 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 of 2 People cross a street dur... |
| 15.09.2025 | Result of General Meeting | Result of General Meeting
Mon, Sep 15, 2025 14:15 CET Report this content
15 September 2025
Fidelity European Trust PLC
Legal Entity Identifier: 549300UC0QPP7Y0W8056
Result of General Meeting
The Board of Fidelity European Trust PLC (the &q... |
| 15.09.2025 | Correction - Result of General Meeting | Correction - Result of General Meeting
Mon, Sep 15, 2025 15:02 CET Report this content
This announcement replaces the “Result of General Meeting” announcement released 13:15:00 on 15 September 2025. The original announcement contained an in... |
| 10.09.2025 | Janus Henderson’s Laura Foll on navigating UK equities and value investing | Laura Foll is co-manager of the Lowland and Law Debenture investment trusts at Janus Henderson, as well as Janus Henderson’s UK Equity Income & Growth open-ended fund.
Later this month, on 17 September, City AM is partnering with Law De... |
| 07.09.2025 | Galvanize Therapeutics Secures $100M: Revolutionizing Oncology and Chronic Lung Disease Treatment | Galvanize Therapeutics landed a significant $100 million Series C financing. This substantial capital propels its innovative pulsed electric field (PEF) therapies. The Redwood City firm targets critical unmet needs in oncology and chronic l... |
| 06.09.2025 | Galvanize Therapeutics: $100 Million Raised For Advancing Therapies For Cancer And Chronic Lung Disease | Galvanize Therapeutics, a commercial-stage medical technology company developing novel pulsed electric field therapies, has announced the successful close of a $100 million Series C financing round. The round was oversubscribed, reflecting ... |
| 04.09.2025 | Half-year Report | Half-year Report
Thu, Sep 04, 2025 08:00 CET Report this content
FIDELITY EUROPEAN TRUST PLC
Half-Yearly Results for the six months ended 30 June 2025 (unaudited)
Financial Highlights: The Board of Fidelity European Trust PLC (the “Company”... |
| 03.09.2025 | Galvanize Therapeutics Raises $100 Million in Oversubscribed Series C Financing to Transform the Treatment of Cancer and Chronic Lung Disease | Sofinnova Partners leads premier investor syndicate backing Galvanize's breakthrough pulsed electric field (PEF) platform—a first-of-its-kind, non-drug approach targeting solid tumors and chronic bronchitis, the leading cause of COPD.
REDWO... |
| 03.09.2025 | Galvanize Therapeutics Raises $100M in Series C Financing | Galvanize Therapeutics, Redwood City, CA-based commercial-stage medical technology company advancing pulsed electric field (PEF) therapies for oncology and chronic lung disease, raised a $100m Series C financing.
The round was led by Sofinn... |
| 01.09.2025 | India's strong economic growth fails to impress equity investors | India's strong economic growth fails to impress equity investors
By Bharath Rajeswaran and Vivek Kumar MSeptember 1, 20258:54 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A man counts Indian ... |
| 29.08.2025 | Treasury yields push slightly higher after in-line PCE report | U.S. Treasury yields were slightly higher on Friday after the Federal Reserve’s preferred inflation gauge came in as expected, while traders monitored President Trump’s attempts to fire Fed Governor Lisa Cook.
The benchmark 10-year Treasury... |
| 21.08.2025 | Correction to Publication of Prospectus and Circular | Correction to Publication of Prospectus and Circular
Thu, Aug 21, 2025 18:01 CET Report this content
CORRECTION TO PUBLICATION OF PROSPECTUS AND CIRCULAR:
This announcement replaces the announcement made at 14:00:00 on 21 August 2025. The t... |
| 21.08.2025 | Publication of Prospectus and Circular | Publication of Prospectus and Circular
Thu, Aug 21, 2025 15:00 CET Report this content
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, ... |
| 11.08.2025 | Equillium: Up To $50 Million Financing Raised To Advance EQ504 | Equillium has secured a securities purchase agreement with leading healthcare investors to raise to $50 million. The financing includes an upfront payment of $30 million for approximately 52.6 million shares or pre-funded warrants at $0.57 ... |
| 01.08.2025 | Everest Medicines Expands Strategic Investment in I-MAB | - Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%.
- I-Mab's Claudin 18.2 x 4-1BB bispecific antib... |
| 09.07.2025 | Kardium: $250 Million Raised For Launching Atrial Fibrillation Treatment | Kardium, the developer of the Globe Pulsed Field System for atrial fibrillation (AF), has raised $250 million in a financing round led by new investors, including Janus Henderson Investors and the Qatar Investment Authority, with participat... |
| 02.07.2025 | Kardium Raises $250M in Funding | Kardium, a Vancouver, Canada-based developer of the globe pulsed field system, a treatment for atrial fibrillation (AF), raised $250M in funding.
The round was led by Janus Henderson Investors, Qatar Investment Authority (QIA), MMCAP, Piper... |
| 28.06.2025 | Wall Street's Balancing Act: Stocks, Tariffs, and Labor Strikes | Wall Street is a tightrope walker, balancing between optimism and uncertainty. Recent stock gains hint at a potential climb to all-time highs. Yet, beneath the surface, tensions brew. The economy is a complex web, woven with threads of trad... |
| 27.06.2025 | Stocks gain ground and put Wall Street on a path for all-time highs | The price of crude oil in the U.S. is mostly unchanged on Friday. Prices have fallen back to pre-conflict levels.
Investors are also monitoring potential progress on trade conflicts between the U.S. and the world, specifically with China. T... |
| 12.06.2025 | Mutual funds vs. ETFs — the difference and the role they can play in your portfolio | - |
| 16.05.2025 | Janus Henderson weighs private equity in MENA after credit strategy | Premium
Erdem Kilic, principal at Janus Henderson Emerging Markets Private Investments
Janus Henderson, a global asset management firm that expanded its presence in the Middle East last year through the acquisition of NBK Capital Partners, ... |
